The ITCC-P4 Advisory Board has begun its work, bringing together complementary perspectives from paediatric cancer research, drug development,…

The Council’s agreement marks a further step towards revising the European framework for medicines, including treatments for children and rare…

EU's Innovative Health Initiative hosts this unique opportunity to engage "In Conversation with... ITCC-P4"

Meet our partnering CROs at the AACR Annual Meeting 2025

On the occasion of Children's Cancer Day on February 15, ITCC-P4 is in the media! Check it out!

A subset of the molecular data characterising ITCC-P4's PDX models is now available for the public.

ITCC-P4 successfully initiated early dialogue with EMA and FDA enabling generation of high-quality preclinical data for regulatory decisions.

EUR 2 million of funding to combat childhood brain tumours

The founding of ITCC-P4 gGmbH has been notaritzed on April 6, 2023. One year later, on April 10, 2024, the founding process was completed by…

Meet us at the AACR Annual Meeting 2024